Message #75 From:
NewsBot Date: October 23, 2006 07:11:00 AM
MIVT News MIV Therapeutics to Detail Research Results Showing Excellent Performance of Breakthrough Stent Coatings at TCT Conference
ATLANTA--(BUSINESS WIRE)--MIV Therapeutics (OTCBB:MIVT)
(FWB:MIV), announced that Dr. Greg Kaluza, Scientific Director, Center
for Research in Cardiovascular Interventions at The Methodist Hospital
Research Institute, Houston, TX, who directed the independent
preclinical study of MIVT’s stent coatings
will present recent results of a long-term animal study of its
proprietary stent coating technology at the Annual Transcatheter
Cardiovascular Therapeutics (TCT) 2006 conference in Washington, D.C.,
the field’s largest scientific meeting.
The latest results extend the evidence of long term safety,
biocompatibility and performance of the Company’s
unique hyrdroxyapatite (HAp) stent coatings.
MIVT’s research was one of only three
abstracts selected for presentation in its subject area.
According to the conclusions that Dr. Kaluza will present at the TCT
meeting, “MIVT’s
exemplary HAp coating features excellent long term biocompatibility and
makes an attractive candidate for next-generation stent coatings.”
Other MIV Therapeutics presentations that will be made at the TCT
include:
The promising results of a first in-vivo study on the use of a
non-polymeric lipid based coated stent delivering an antirestenotic
agent.
The encouraging results of a first in-vivo study of an
electrochemically deposited HAp coated stent eluting a combination of
multiple antirestenotic drugs.
“These key findings from recent trials have
provided the necessary evidence that we have excellent candidates to
address the market's demand for a safer drug eluting stent and allows us
to move our platforms to the next phase in their development,”
said Dr. Mark Landy, President of MIV Therapeutics.
TCT is the largest interventional vascular medicine symposium in the
world, with attendance by more than 10,000 physicians, health care
providers and industry professionals specialized in the field of
interventional vascular therapy. TCT has become the premiere venue to
introduce groundbreaking and pioneering innovations in this field.
Acceptance to present at the conference represents an important
recognition of the significance of MIVT’s
proprietary technology.
“The TCT conference is one of the most
important events in our field. Only a small proportion of abstracts are
selected every year to be presented as oral presentations at the TCT
conference, and I am very pleased that our research was found by TCT’s
professional reviewers worthy of this exposure,”
said Dr. Landy. “This strengthens MIVT’s
growing reputation for scientific leadership as we continue on our path
to commercialization and address the market's demand for a safer drug
eluting stent.”
At the conference, Dr. Kaluza will deliver an abstract entitled, “Exemplary
Long-Term (Six Month) Biocompatibility of a Novel Ultra-Thin
Hydroxyapatite Stent coating in Normal Porcine Coronary Arteries.”
Co-authors include chief study pathologist Dr. Fred J. Clubb, Jr. and
members of MIVT’s research team. The
presentation will take place on the 25th
October at the TCT in room 145AB at 10:15am.
About Transcatheter Cardiovascular Therapeutics 2006
Transcatheter Cardiovascular Therapeutics (TCT), sponsored by the
Cardiovascular Research Foundation®, is a
scientifically stimulating symposium for physicians and other health
care professionals who specialize in the field of interventional
vascular therapy. This year’s event is
scheduled for October 22-27, 2006, Washington Convention Center,
Washington, D.C. For more information, please visit http://www.tct2006.com.
About The Methodist Hospital Research Institute
The Methodist Hospital Research Institute in Houston, TX, is a
cornerstone of The Methodist Hospital's strategic vision for its future
as a top-ranked academic medical center. The Research Institute is
committed to moving the latest discoveries in the laboratory to the
bedside in order to provide a new standard of care for our patients in
Houston and in other parts of the country. For more information on The
Methodist Hospital and the Methodist Hospital Research Institute, see http://www.methodisthealth.com/.
About MIV Therapeutics Inc.
MIV Therapeutics is developing a next-generation line of advanced
biocompatible coatings for passive and drug-eluting applications on
cardiovascular stents and a broad range of other implantable medical
devices. The Company’s ultra-thin coating
formulation is designed to protect surrounding tissue from potentially
harmful interactions with bare metallic stents. The Company’s
unique ultra-thin coating platform is derived from an organic material
called hydroxyapatite (HAp) which has demonstrated excellent safety and
biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive
porous material that makes up the bone mineral and matrix of teeth and
is widely used today as a bone substitute material and for coatings on
implantable fixation devices in orthopedic, dental and other
applications. The Company’s novel
polymer-free drug eluting technologies based on Hydroxyapatite could
also provide an attractive alternative to current polymer-based drug
eluting coatings on the stent market, which have been associated with
undesirable medical effects. The Company’s
drug eluting coatings are additionally designed to suit a broad range of
implantable medical devices that could benefit from highly customizable
drug release profiles. MIVT has a Collaborative Research Agreement (CRA)
with the University of British Columbia and has received Government
grant for its research program on the “Development
of Novel Drug Eluting Composite Coatings for Cardiovascular Stents,”
under the National Research Council-Industrial Research Assistance
Program (NRC-IRAP). Under this sponsorship, the Company is expected to
complete its drug-eluting research and development program and to reach
product commercialization stage. For more information, please visit http://www.trilogycapital.com/tcp/mivt/website.html.
To read or download MIV Therapeutics’
Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html.
To obtain daily and historical Company stock quote data, and recent
Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.
MIVT is traded on the Frankfurt, Germany, stock exchange under the
symbol MIV.
Forward-Looking Statements
Except for the historical information contained herein, the matters
discussed in this press release are forward-looking statements. Such
statements are indicated by words or phrases such as “believe,”“will,”“breakthrough,”“significant,”“indicated,”“feel,”“revolutionary,”“should,”“ideal,”“extremely” and “excited.”
These statements are made under “Safe Harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those described in
forward-looking statements and are subject to risks and uncertainties.
See the Company’s filings with the Securities
and Exchange Commission including, without limitation, the Company’s
recent Form 10-K and Form 10-Qs, which identify specific factors that
may cause actual results or events to differ materially from those
described in the forward-looking statements.
